一分钟看懂
这是一项关于淋巴瘤的I 期研究，登记的药物或干预包括LP-168 tablet，当前状态为招募中。登记地点显示中国北京、广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
LP-168 tablet · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Third Hospital · 北京
- Beijing Cancer Hospital · 北京
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- * Per 2017 revised WHO lymphoma classification criteria, subject must have either:
- Diagnosed with relapsed or refractory DLBCL or FL and require treatment in the opinion of the Investigator and have received 2 lines SOC.
- Diagnosed with relapsed or refractory non-Hodgkin's lymphoma associated with B-cell proliferation (such as CLL\\ SLL \\ MCL \\ MZL \\ WM, etc.) in need of treatment in the opinion of the Investigator and have received 1 line SOC.
- * Adequate hematologic function.
- * Adequate hepatic and renal function.
- * Ability to receive study drug therapy orally and willing to receive examinations.
- * Willingness of men and women of reproductive potential (defined as following menarche and not postmenopausal \[and 2 years of non-therapy-induced amenorrhea\] or surgically sterile) to observe conventional and effective birth control.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04993690；登记信息更新于 2026-09-14。